● Acquisition positions Chiesi to expand patient access
to approved treatments and advance efforts to develop new
treatments for people living with rare diseases.
PARMA, Italy, DUBLIN
and BOSTON, MA,
April 12,
2023 /PRNewswire/ -- Chiesi Farmaceutici S.p.A.
("Chiesi"), an international, research-focused biopharmaceuticals
and healthcare group, today announced the completion of the
acquisition of Amryt Pharma Plc ("Amryt") (Nasdaq: AMYT), a global,
commercial-stage biopharmaceutical company dedicated to acquiring,
developing, and commercializing novel treatments for rare
diseases.
"We are excited to add the Amryt family to our company in
this acquisition that demonstrates our commitment to rare diseases
and aligns with our growth strategy through partnerships beyond
internal research and development," said Giacomo Chiesi, head of Chiesi Global Rare
Diseases. "Amryt has unique and clinically differentiated
products and additional promising drugs in its pipeline, and, as a
benefit corporation certified B Corp, Chiesi has a patient-centric
and sustainable model in place to make these treatments available
to even more patients who need them. As of today, we are officially
joining our forces to bring hope to people in need and look forward
to this new chapter in our collective journey."
"This acquisition reflects Chiesi Group's commitment towards
patients. Chiesi strives to create a world where it is common to
have a therapy for all diseases and acts as a force for good for
society and the planet," said Giuseppe Accogli, CEO of Chiesi Group
"Amryt Pharma's team has delivered innovative treatments to rare
disease patients with high unmet medical needs. By joining forces
and expertise we will be able to grow our capabilities and further
strengthen our position to provide a positive impact on patients
living with rare diseases."
About Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is a business unit of the Chiesi
Group established to deliver innovative therapies and solutions for
people affected by rare diseases. As a family business, Chiesi
Group strives to create a world where it is common to have a
therapy for all diseases and acts as a force for good, for society
and the planet. The goal of the Global Rare Diseases unit is to
ensure equal access so as many people as possible can experience
their most fulfilling life. The unit collaborates with the rare
disease community around the globe to bring voice to underserved
people in the health care system. For more information visit
www.chiesirarediseases.com.
About Chiesi Group
Chiesi is an international, research-focused biopharmaceuticals
group that develops and markets innovative therapeutic solutions in
respiratory health, rare diseases, and specialty care. The
company's mission is to improve people's quality of life and act
responsibly towards both the community and the environment. By
changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi's commitment to create shared
value for society as a whole is legally binding and central to
company-wide decision-making. As a certified B Corp since 2019,
we're part of a global community of businesses that meet high
standards of social and environmental impact. The company aims to
reach Net-Zero greenhouse gases (GHG) emissions by 2035. With over
85 years of experience, Chiesi is headquartered in Parma
(Italy), operates in 31 countries,
and counts more than 6,500 employees. The Group's research and
development centre in Parma works alongside 6 other important
R&D hubs in France, the US,
Canada, China, the UK, and Sweden.
For further information please visit www.chiesi.com
About Amryt
Amryt is a global commercial-stage biopharmaceutical company
focused on acquiring, developing and commercializing innovative
treatments to help improve the lives of patients with rare and
orphan diseases. Amryt comprises a strong and growing
portfolio of commercial and development assets. For more
information on Amryt, including products, please visit
www.amrytpharma.com.
Media Contact:
Chiara Travagin
Rare Communication Manager
Mob. +39 348
8818985
c.travagin@chiesi.com
Alessio Pappagallo
Press Office Manager
Mob: +39 339 5897483
a.pappagallo@chiesi.com
Jenna Urban
Berry & Company Public Relations
1-212-253-8881
jurban@berrypr.com
View original
content:https://www.prnewswire.com/news-releases/chiesi-farmaceutici-spa-completes-acquisition-of-amryt-pharma-plc-301795487.html
SOURCE Chiesi
